Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

This study has been terminated.
(could not enroll patients)
Sponsor:
Collaborator:
Bukwang Pharmaceutical
Information provided by:
Inje University
ClinicalTrials.gov Identifier:
NCT00798460
First received: November 25, 2008
Last updated: June 22, 2011
Last verified: June 2011
  Purpose

The purpose of this study is to determine the optimal antiviral treatment for lamivudine resistant hepatitis B patients.


Condition Intervention Phase
Chronic Hepatitis B
Drug: adefovir
Drug: clevudine
Drug: lamivudine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Controlled Tial of Combination Therapy for Lamivudine-resistant Chronic Hepatitis B Patient: Comparing Clevudine Plus Adefovir With Lamivudine Plus Adefovir

Resource links provided by NLM:


Further study details as provided by Inje University:

Primary Outcome Measures:
  • HBV DNA titer < 300 copies/mL [ Time Frame: 48 week ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Normalization of serum ALT, loss of HBeAg and HBsAg, incidence of adefovir resistance [ Time Frame: 48 week ] [ Designated as safety issue: Yes ]

Enrollment: 30
Study Start Date: December 2008
Study Completion Date: November 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Lamivudine plus adefovir Drug: adefovir
adefovir 10mg
Other Name: Hepsera
Drug: lamivudine
lamivudine 100mg
Other Name: Zeffix
Active Comparator: Clevudine plus adefovir Drug: adefovir
adefovir 10mg
Other Name: Hepsera
Drug: clevudine
clevudine 30mg
Other Name: Levovir

Detailed Description:

Lamivudine with adefovir combination therapy has been known as effective antiviral therapy for lamivudine resistant chronic hepatitis B patients. It is superior to adefovir monotherapy since the incidence of viral breakthrough of combination therapy used to be less than that of adefovir monotherapy in lamivudine resistant chronic hepatitis B patients. Clevudine, which is being marketed in Korea, is a nucleoside analogue of the unnatural beta-L configuration that has potent activity against HBV. It has demonstrated potent antiviral efficacy and significant biochemical improvement after 24 weeks of therapy. We hypothesized that clevudine plus adefovir combination therapy for lamivudine resistant patients might be as effective as the lamivudine plus adefovir combination therapy.

In detail, we designed to perform this clinical study comparing the combination of clevudine and adefovir with lamivudine plus adefovir in lamivudine resistant chronic hepatitis B patient. Total treatment duration of both groups will be 12 months, and compare the efficacy of antiviral effects of these drugs.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HBsAg positive and anti-HBs negative more than 6 months
  • YMDD mutation (+)during lamivudine therapy
  • Serum ALT more than two times upper normal value

Exclusion Criteria:

  • HAV IgM Ab + and/or HCV Ab+ and/or HDV Ab and/or HIV Av+
  • The sign of decompensated liver disease
  • Pregnant or lactating woman
  • The history of hemoglobinopathy, autoimmune hepatitis, alcoholic liver disease
  • Hemoglobin less than 8 g/dL (male), 7.5g/dL (female) or neutrophil count less than 1500/mm3 or platelet count less than 50,000/mm3
  • Serum creatinine more than 1.5 times upper normal limit value
  • The sign of malignancy or suggestive of malignancy or the history of malignancy, the recurrence rate within 2 years of which is more than 20%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00798460

Locations
Korea, Republic of
Ilsanpaik hospital
Goyang, Gyunggi, Korea, Republic of, 411-706
Sponsors and Collaborators
Inje University
Bukwang Pharmaceutical
Investigators
Principal Investigator: June Sung Lee, M.D. Department of Internal Medicine, Ilsanpaik hospital, Inje Univeristy, 2240 Daewha-dong, Ilsanseo-gu, Goyang, Gyunggi, Korea, 411-706
  More Information

No publications provided

Responsible Party: June Sung Lee, Ilsanpaik hospital, Inje University
ClinicalTrials.gov Identifier: NCT00798460     History of Changes
Other Study ID Numbers: IB-0809-055
Study First Received: November 25, 2008
Last Updated: June 22, 2011
Health Authority: Korea: Food and Drug Administration

Keywords provided by Inje University:
Chronic hepatitis B
lamivudine resistance
clevudine

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
DNA Virus Infections
Digestive System Diseases
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Adefovir
Adefovir dipivoxil
Clevudine
Lamivudine
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014